Brief: Calliditas Therapeutics Q2 Operating Loss Widens To SEK 209.8 Mln
18/08/2022 06:22
Aug 18 (Reuters) - Calliditas Therapeutics AB CALTX.ST :
* Q2 OPERATING LOSS SEK 209.8 MILLION VERSUS LOSS SEK 159.4
MILLION YEAR AGO
* INTERIM REPORT Q2, 2022
* Q2 NET SALES AMOUNTED TO SEK 64.0 MILLION
* LOSS PER SHARE BEFORE AND AFTER DILUTION AMOUNTED TO SEK
3.62
AND SEK 3.22 FOR THREE MONTHS ENDED JUNE 30, 2022 AND 2021,
RESPECTIVELY.
Source text for Eikon: ID:nNDL9KxgpT
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations